Non-small cell lung cancer nonsquamous · 6 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carboplatin, Pemetrexed, Durvalumab N/A - protocol | — | R 265 140 | 28d | — | — | — | — | — |
Cisplatin, Pemetrexed, Durvalumab N/A - protocol | — | R 264 489 | 28d | — | — | — | — | — |
Cisplatin, Pemetrexed, Pembrolizumab Variant #01 | — | R 83 075 | 21d | — | — | — | — | 1 |
Carboplatin and Paclitaxel (CP) and Nivolumab Variant #01 Partial | — | R 2 239 | 21d | — | — | — | — | 3 |
Carboplatin, Pemetrexed, Nivolumab Variant #01 Partial | — | R 1 738 | 28d | — | — | — | — | — |
Cisplatin, Pemetrexed, Nivolumab Variant #01 Partial | — | R 1 088 | 21d | — | — | — | — | 1 |
6 of 6 regimens shown